MCL Literature Feed

This review provides a framework for selecting frontline therapies for older MCL patients, weighing less-intensive chemoimmunotherapy against novel agents like BTK inhibitors based on patient-specific factors.

This review details the oncogenic role of the FoxO1 transcription factor in MCL, highlighting its potential as a novel therapeutic target with specific preclinical inhibitors under investigation.

This review details how MCL cell adhesion within the microenvironment promotes survival, explaining the mechanism of action for TME-disrupting therapies and its role in drug resistance.

This review summarizes advanced 3D culture models that better mimic the MCL microenvironment, offering improved platforms for preclinical drug screening and developing personalized medicine.

This review argues that new agents like BTKi are disrupting the frontline MCL standard of care, challenging ASCT's role and demanding personalized, risk-adapted treatment guidelines to resolve clinical uncertainty.

This review summarizes the integration of BTK inhibitors into frontline MCL therapy and the emerging role of MRD, providing a treatment algorithm for managing newly diagnosed patients.

A rare case of composite CLL/MCL highlights diagnostic challenges from overlapping immunophenotypes, reinforcing the critical need for molecular and cytogenetic studies like FISH for t(11;14) for definitive diagnosis.

This case report demonstrates that secondary prostatic MCL can mimic prostate cancer, and transurethral resection can effectively manage resultant urinary retention, highlighting a rare extramedullary presentation.

This review characterizes the rare transformation of MCL into aggressive Burkitt lymphoma, a distinct form of Richter's syndrome, highlighting its unique pathogenesis, clinical features, and poor prognosis.

A commentary on a 40-year retrospective analysis confirms that therapeutic advances have led to gradual but significant improvements in overall survival for mantle cell lymphoma patients.

This review of CAR-T for MCL highlights the critical need for structured collaboration between specialized centers and community practices to manage toxicities and ensure successful patient outcomes.

This review outlines key clinical strategies for patient selection, toxicity management, and overcoming resistance to maximize the efficacy and safety of CAR-T therapy in relapsed/refractory MCL.

This review summarizes recent phase II/III trial data supporting the integration of covalent BTK inhibitors into frontline MCL therapy, proposing new treatment algorithms for this setting.

This review outlines emerging treatment strategies for relapsed/refractory MCL patients who progress after CAR-T therapy, addressing a significant and growing unmet clinical need in this setting.

This review of FDA-approved covalent inhibitors highlights the foundational role of BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) in MCL, which established this successful drug development strategy.

This review outlines strategies like non-viral vectors, allogeneic products, and point-of-care manufacturing to reduce CAR-T therapy costs, potentially increasing access for relapsed/refractory MCL patients.

This conference report identifies key controversies in B-cell lymphoma management, initiating a formal process to develop expert consensus guidelines for navigating increasingly complex treatment selection and sequencing decisions.

This review outlines the evolving MCL treatment paradigm, emphasizing earlier BTKi use, established CAR-T, and emerging non-covalent BTKi and bispecifics for high-risk disease like TP53-mutated MCL.

This review contrasts European and American perspectives on integrating autologous transplant, CAR-T, and allogeneic transplant into MCL treatment, offering clinical guidance in a rapidly evolving therapeutic landscape.

This review highlights ongoing trials moving CAR-T and bispecific antibodies into earlier lines of MCL therapy, signaling a potential paradigm shift away from traditional chemoimmunotherapy.

The recent FDA approval of Lisocabtagene Maraleucel provides a new CAR-T therapy for relapsed/refractory MCL, offering high response rates but requiring careful management of severe toxicities.

This review summarizes current MCL risk stratification (MIPI, TP53), highlights emerging genomic biomarkers, and emphasizes MRD monitoring as a key dynamic tool for personalizing therapy, especially for high-risk patients.

This review advocates for adding a BTKi to frontline immunochemotherapy for transplant-eligible patients as a new standard of care, while also summarizing its emerging role in older patients.

This myeloma review outlines strategies to overcome proteasome inhibitor resistance by targeting other proteostasis pathways, providing a rationale for exploring similar combinations in relapsed/refractory MCL.

This review provides a practical guide for differentiating aggressive B-cell lymphomas, including mantle cell lymphoma, emphasizing the integration of morphology, immunohistochemistry, and molecular testing for accurate diagnosis and classification.

This review summarizes favorable outcomes for CAR-T and bispecific antibodies in relapsed/refractory MCL, detailing their integration into the treatment paradigm for patients with poor prognoses post-BTKi.

This review synthesizes mechanisms of BTKi resistance and highlights next-generation strategies like noncovalent BTKi and PROTACs to overcome this critical challenge in relapsed/refractory MCL.

This review provides a practical guide for clinicians on the approved indications and real-world application of anti-CD19 CAR-T cell therapy for mantle cell lymphoma.

This case report of primary colonic MCL presenting with intussusception highlights surgery's crucial role in diagnosis and managing complications for rare, localized extranodal disease before systemic therapy.

This correspondence provides expert commentary and clarification on the pivotal trial data for the bispecific antibody glofitamab in patients with relapsed/refractory mantle cell lymphoma.